Adjunct Professor of Medicine, Department of Cardiology, David Geffen School of Medicine at UCLA
Dr. Mohamad Navab is a Professor in the Departments of Medicine, Cardiology at the David Geffen School of Medicine at UCLA, with 32 years of research experience in the study of atherosclerosis, lipids and artery wall metabolism. His work has been continuously supported by the National Institutes of Health (NIH). He is CoProject Leader on an NIH PPG/grant that is going into its 31st year. He has published 195 peer-reviewed articles (average H index 90), including 100 chapters and reviews, co-edited two books, and organized three interdisciplinary symposia in the area of lipids and artery wall metabolism. His current research focus is on the role of the role of small intestine, systemic inflammation and cardiovascular function. He has been involved in studies of gut microbiota in dyslipidemia and the effect of HDL mimetic peptides on it.
Relevant Recent Publications
Source and role of intestinally derived lysophosphatidic acid in dyslipidemia and atherosclerosis. Navab M et al. J Lipid Res. 2015;56:871-87
Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid. Navab M, et al. J Lipid Res. 2013;54:3403-18
Intestine may be a major site of action for the ApoA-I mimetic peptide 4F whether administered subcutaneously or orally. Navab M, et al. J Lipid Res. 2011; 52:1200-10.
HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Navab M, Nat Rev Cardiol. 2011;8:222-32
Mechanisms of disease: proatherogenic HDL–an evolving field. Navab M, Nat Clin Pract Endocrinol Metab. 2006 ;2:504-11.